<!doctype html><html lang=tw><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>歌禮制藥-B(01672)：THR-BETA受體激動劑非酒精性脂肪性肝炎藥ASC41臨床試驗申請獲批 | 极客快訊</title><meta property="og:title" content="歌禮制藥-B(01672)：THR-BETA受體激動劑非酒精性脂肪性肝炎藥ASC41臨床試驗申請獲批 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="tw"><meta property="og:image" content><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/7a4173c.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/7a4173c.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/7a4173c.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/7a4173c.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/7a4173c.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/7a4173c.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/7a4173c.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/7a4173c.html><meta property="article:published_time" content="2020-10-29T20:57:50+08:00"><meta property="article:modified_time" content="2020-10-29T20:57:50+08:00"><meta name=Keywords content><meta name=description content="歌禮制藥-B(01672)：THR-BETA受體激動劑非酒精性脂肪性肝炎藥ASC41臨床試驗申請獲批"><meta name=author content="极客快訊"><meta property="og:url" content="/tw/%E7%A7%91%E5%AD%B8/7a4173c.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快訊 Geek Bank</a></h1><p class=description>為你帶來最全的科技知識 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>歌禮制藥-B(01672)：THR-BETA受體激動劑非酒精性脂肪性肝炎藥ASC41臨床試驗申請獲批</h1></header><date class="post-meta meta-date">2020-10-29</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=tw/categories/%E7%A7%91%E5%AD%B8.html>科學</a></span></div><div class=post-content><p>智通財經APP訊，歌禮制藥-B(01672)發佈公告，公司內部研發的一類藥ASC41已獲得中國國家藥品監督管理局(NMPA)批准進行非酒精性脂肪性肝炎(NASH)適應症的臨床試驗(IND)。</p><p>公司的NASH管線中有另外兩款在研藥物：處於臨床試驗II期的ASC40以及一款IND前在研藥物。ASC41有望單獨使用或與ASC40或IND前在研藥物聯合使用。ASC41是一款口服甲狀腺激素β受體(THR-beta)激動劑，而ASC40則是一款口服脂肪酸合成酶(FASN)抑制劑。</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>歌禮</a></li><li><a>制藥</a></li><li><a>01672</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list><li><a href=../../tw/%E7%A7%91%E5%AD%B8/f8ea5e7.html alt=歌禮制藥-B(01672)：甘萊NASH候選藥物ASC42(FXR激動劑)於美國獲批IND class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/f8ea5e7.html title=歌禮制藥-B(01672)：甘萊NASH候選藥物ASC42(FXR激動劑)於美國獲批IND>歌禮制藥-B(01672)：甘萊NASH候選藥物ASC42(FXR激動劑)於美國獲批IND</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/5e1d800a.html alt=聯邦制藥(03933)：治活動性類風溼性關節炎新藥WXSH0150獲臨床試驗通知書 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/5e1d800a.html title=聯邦制藥(03933)：治活動性類風溼性關節炎新藥WXSH0150獲臨床試驗通知書>聯邦制藥(03933)：治活動性類風溼性關節炎新藥WXSH0150獲臨床試驗通知書</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/f22a3bb0.html alt=聯邦制藥：做“走出去”的先行者 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p3.pstatp.com/large/471c000017cf9ed46dfb style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/f22a3bb0.html title=聯邦制藥：做“走出去”的先行者>聯邦制藥：做“走出去”的先行者</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/74872656.html alt=嘉應制藥2017年年度董事會經營評述 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/74872656.html title=嘉應制藥2017年年度董事會經營評述>嘉應制藥2017年年度董事會經營評述</a></li><hr><li><a href=../../tw/%E7%A7%91%E5%AD%B8/bd9f9fd.html alt=歌禮THR-beta激動劑ASC41獲批開展NASH適應症臨床試驗 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/bd9f9fd.html title=歌禮THR-beta激動劑ASC41獲批開展NASH適應症臨床試驗>歌禮THR-beta激動劑ASC41獲批開展NASH適應症臨床試驗</a></li><hr></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>